Progress of PI3K﹣AKT﹣mTOR signaling pathway in pathogenesis and targeted therapy of pediatric Burkitt lymphoma

VernacularTitle:PI3K﹣AKT﹣mTOR信号通路在儿童伯基特淋巴瘤发病机制及靶向治疗中的研究进展
Author: Jie MAN ¹ ; Xiaowen ZHAI
Author Information

1. 复旦大学附属儿科医院血液科
Keywords: PI3K﹣AKT﹣mTOR; Burkitt lymphoma; Child; Molecular targeted therapy
From: Journal of Leukemia & Lymphoma 2019;28(7):445-448
CountryChina
Language:Chinese
Abstract: Burkitt lymphoma (BL) is a highly aggressive mature B﹣cell lymphoma originating from the germinal center, and accounts for 30%-50% of childhood non﹣Hodgkin lymphoma (NHL). The current dose﹣intensive, multi﹣agent chemotherapy has made great progress in the treatment of BL with the cure rate of 80%-90%; however, the relapse or death rate still remains 10%-20% due to toxicity of such therapy. Studies have shown that abnormal activation of PI3K﹣AKT﹣mTOR signaling pathway and abnormal expression of key regulatory genes are closely related to the pathogenesis, development, treatment and prognosis of BL. This article will review the abnormal activation mechanisms of PI3K﹣AKT﹣mTOR signaling pathway and targeted therapy of pediatric BL to further clarify the pathogenesis and potential targets for drug therapy of pediatric BL at the molecular and genetic levels.